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Background: Identification of different HPV subtypes in unidentified communities provides sufficient information
for screening and monitoring potential impact of a vaccination program. Therefore, the aim of this study was to
screen for the presence of HPVs subtypes 31,33,35,39 and 45 among Yemeni women with Cervical Cancer.
Methodology: A total of 200 (150 malignant and 50 benign) tissue samples were obtained from Yemeni women
with cervical cancer, were investigated for the presence of HPV subtypes 31,33,35,39 and 45 by Polymerase Chain
Reaction (PCR).
Results: Of the 150 cervical cancer tissue specimens, HPV 31, HPV 33, HPV35, HPV 39 and HPV45 were identified in
10/150 (6.7 %), 6/150 (4 %), 6/150 (4 %), 5/150 (3.3 %) and 10/150 (6.7 %), respectively. The frequency of these HPV
subtypes among Yemeni women with cervical cancer was 24 %. Conclusion: HPV 31, HPV 33, HPV35, HPV 39 and
HPV45 were prevalent among Yemeni women with cervical cancer.
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Cervical cancer is the third most common cancer in
women Worldwide [1]. Oncogenic human papillomavi-
rus (HPV) is the most important risk factor associated
with cervical cancer [2]. HPV have been divided into
high- and low-risk on the basis of their oncogenic poten-
tial. High risk HPV is considered to be the leading etio-
logical cause for cervical cancer [3]. Cervical cancer is
one of the most common cancers among women world-
wide [4]. Cervical cancer is a very slow progressive dis-
ease which needs prolonged period to progress from
normal to pre-cancer and to the potentially fatal invasive
cancer. There is a gap of 10–20 years between pre-
cancer and cancer which offers an opportunity to screen,
detect and treat pre-cancer and avoid its progression to
cancer. Immunocompromised women, however, progress* Correspondence: hussaingad1972@yahoo.com
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article, unless otherwise stated.more frequently and more quickly to pre-cancer and
cancer [5, 6].
Infection with high-risk human papillomavirus (HR-
HPV) is established as the main cause of cervical carcin-
oma [7]. HPV has been involved in 99.7 % of cervical
squamous cell cancer cases worldwide [8]. Human Papil-
loma Virus (HPV) is small DNA virus commonly infect-
ing mucosa and cutaneous keratinocytes. Up to now, at
least 200 HPV genotypes are known. HPV have been di-
vided into high- and low-risk on the basis of their onco-
genic potential. High risk HPV is considered to be the
leading etiological cause for cervical cancer [3]. Low-risk
HPV types include types 6, 11, 42, 43, and 44. High-risk
HPV types include types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59, 68, 73, and 82 [9].
The L1 and L2 proteins form icosahedral capsids for
progeny virion generation. Based on sequence variation
of the L1, L2, HPV variants differ in biological and
chemical properties, as well as geographical distribution
[10–12]. Intratypic sequence variation has also been
found in the E2, E4, E5, E6, and E7 genes of HPV-16
[10]. The E6 and E7genes encode viral oncoproteins that
target Rb and p53, respectively. During the viral lifele is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 PCR steps. Cycle's time temp PCR steps
Step Temperature °C Time Cycles
1 95 °C Pause
2 95 °C 15 min 1
3 95 °C 30 s 42
63 °C 30 s
72 °C 40 s
4 72 °C 1 min 1
5 10 °C Storage
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somes and stimulate differentiated cells to reenter the S
phase [12]. The oncogenicity of specific HPV variants
appears to vary geographically ethnically [10, 11]. In
2012, the International Agency for Research on Cancer
concluded that there was consistent and sufficient epi-
demiological, experimental and mechanistic evidence of
carcinogenicity to humans for HPV31, HPV33, HPV35,
HPV39, HPV45, for cervical cancer. Consequently, these
types were regarded as 1A carcinogens. They all belong
to the family of the α-Papillomaviridae, in specific to the
species, α7 (HPV39, HPV45) and α9 (HPV31, HPV33,
HPV35) [13].
However, there are very limited studies about HPVs
and their related cancers in the majority of developing
countries such as the greater Middle East which includ-
ing Yemen and its neighboring countries, such as Saudi
Arabia, Qatar, United Arab Emirates [14]. However,
most of the studies in this context have focused on HPV
subtypes 16 and 18 ignoring other high risk or low risk
HPV subtypes. Therefore, the aim of this study was to
find out the prevalence of HPV 31, HPV 33, HPV35,
HPV 39 and HPV45 among Yemeni women with cer-
vical cancer.
Materials and methods
In this study, 200 formalin fixed paraffin wax processed
tissue samples of cervical lesions were obtained from
formerly operated patients from National Cancer Cen-
ters and different histopathology laboratories in Sana’a,
Hadhramout and Aden, Yemen. All specimens and data
were obtained from the archive of National Cancer Cen-
ters, and different hospitals and different private histo-
pathology laboratories in the three governorates mention
above during the period from 2008 to 2012 (full coverage).
Cancer specimens included: Squamous Cell Carcinoma
(SCC), Adenocarcinoma (Ad), Adenosquamo-Carcinoma
(AdSC).
DNA extraction
DNA was extracted from paraffin-embedded samples, by
immersing tissue section in xylene to dissolve the paraf-
fin from the tissue, and then rehydrated using a series of
ethanol washes. Proteins and harmful enzymes such as
nucleases were digested by proteinase K. Buffer contain-
ing denaturing agent (sodium dodecyl sulfate (SDS)),
was added to facilitate digestion [15]. Nucleic acids were
purified from the tissue lysate using buffer-saturated
phenol and high speed centrifugation. Following phenol
extractions, RNase A was added to eliminate contamin-
ating RNA. Additional phenol extractions following in-
cubation with RNase A were used to remove any
remaining enzyme. Sodium acetate and isopropanol were
added to precipitate DNA, and high speed centrifugationwas used to pellet the DNA and facilitate isopropanol re-
moval. Washing with 70 % ethanol was performed to re-
move excess salts, followed by centrifugation to re-pellet
the DNA [16, 17]. DNA is re-suspended in distilled
water, quantified and stored at −20 °C Purified DNA was
subsequently used in downstream applications of PCR.DNA quantification
To evaluate the DNA quantification after DNA extrac-
tion, we had analyzed DNA measurement using a Nano-
Drop spectrophotometer.Amplification of HPV
Type specific primers (primer for HPV 31, HPV 33,
HPV35, HPV 39 and HPV45) were used to detect
HPV31, 33, 35, 39 and 45 DNA in cervical benign and
malignant lesions, adopting the classification procedure
of the American Joint Committee on Cancer (AJCC)
TNM classification and the International Federation of
Gynecology and Obstetrics (FIGO) staging system for
cervical cancer [18]. Amplification was performed ac-
cording to HPV31, 33, 35, 39 and 45 kit from Sacace-
Biotechnologies S.r.l. Caserta –Italy. The final reaction
volume of 40 μl containing 20 μl mix-1 (contained in
PCR tubes), 10 μl of mix-2 and 10 μl of extracted DNA
(sample). Negative control, and positive HPV31,33,35,39
and 45 DNA tubes contained 10 μl of DNA buffer, 10 μl
of HPV31,33,35,39 and 45 were applied.
Samples and controls were amplified using Gene Amp
PCR system 9700. The PCR programis described in
Table 1.Gel-electrophoresis
The PCR products were visualized in 2 % Agarose gel
with 0.5 μg/ml Ethidium bromide. Ten micro liters of
100 bp DNA ladder and PCR product was loaded on the
gel. Gel electrophoresis was performed at 120 V and
36 mA for 60 min. Pictures were taken by Gel documen-
tation system (Gel mega, digital camera and software in
a computer).
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According to manufacture HPV31, 33, 35, 39 and 45 kit
(Sacace-Biotechnologies S.r.l. Caserta –Italy) manual, the
PCR product length for HPV 31 should be 520 bp, HPV
33 should be 227 bp, HPV 35 should be 280 bp, HPV 39
should be 340 bp, HPV 45 should be 475 bp.
Data analysis
Data management was done by using the Statistical Pack-
age for Social Sciences (SPSS version 16). SPSS was used
for analysis and to perform Fisher exacttest for statistical
significance (P value <0.05 was considered significant).
The 95 % confidence level and confidence intervals were
used.
Ethical consideration
Before the study conducted the proposal of the study
were ethically approved by ethical committee of the Sudan
University of Science and Technology. Then the inform
consent were agreed by the general managers of all na-
tional cancer centers, hospitals and private histopathology
laboratories in which the study were performed.
Results
In this study we investigated 200 formalin fixed paraffin
wax tissue blocks obtained from patients previously pre-
sented with cervical lesions (150 were diagnosed with
cervical cancer and 50 with benign cervical lesions). The
ages of the studied group were ranging from 21 to
75 years with a mean age of 47 years. Of the 150 cervical
cancer tissue specimens, HPV 31, HPV 33, HPV35, HPV
39 and HPV45were identified in 10/150 (6.7 %), 6/150
(4 %), 6/150 (4 %), 5/150 (3.3 %) and 10/150 (6.7 %), re-
spectively. Of the 50 benign cervical lesions tissue speci-
mens, HPV 31, HPV 33, HPV35, HPV 39 and HPV45
were identified in 1/50 (2 %), 1/50 (2 %), 1/50 (2 %), 0/
50 (0 %) and 1/50 (2 %), respectively, as indicated in
Fig. 1.
Co-infection was only identified between HPV31 and
























Fig. 1 Description of HPV subtypes by Lesion typewhich gives a prevalence of 36/150 (24 %) for HPV sub-
types (31,33,35 and 45).
Table 2 Summarizesthe distribution of the cervical
cancer cases by type of cancer and HPV subtype. Most
of HPV subtypes were identified within squamous cell
carcinoma tissues. HPV31, HPV33, HPV35, HPV39 and
HPV45, were identified in 8/11 (72.7 %), 5/7 (71.4 %), 5/
7 (71.4 %), 5/5 (100 %), 8/11 (72.7 %) respectively, as in-
dicated in Fig. 2.
The frequencies of infection rates among different age
groups were summarized in Table 3. For HPV31, the
highest infection rate was found among age groups 36–
45 years followed by 46–55 and 56+, representing 6/11
(54.4 %), 4/11 (36.4 %) and 1/11 (9 %), respectively. For
HPV33, the highest infection rates were seen among age
groups <35 years, followed by 36–45, and 46–55 years,
representing 3/7 (42.9 %), 2/7 (28.6 %) and 2/7 (28.6 %).
Regarding HPV35, the highest infection rates were seen
among age ranges, 56+ years representing3/7 (42.9 %)
followed by 45–55, 36–45 and <35 years, constituting 2/
7 (28.6 %), 1/7 (14.3 %) and 1/7 (14.3 %), respectively.
HPV39, has showed high rates of infection among age
ranges <35 and 46–55 years representing 2/5 (40 %) for
each. HPV45 has denoted high infection rates among
age groups 36–45 years, representing 4/11 (36.4 %),
followed by age ranges 56+,<30 and 46–55 years, consti-
tuting 3/11 (27.3 %), 2/11 (18.2 %) and 2/11 (18.2 %), in
this order.
With respect to the residence, most of cases of Cervical
Cancer were coming from Al-Janad representing 52/200
(26 %) followed by Aden constituting 45/200 (22.5 %), as
shown in Fig. 3. In regard to the residence and HPV infec-
tion, the great majority of infections were identified
among Al-Janad populations, representing 14/43 (32.6 %)
followed by Aden, Azaal, Tohama Hadhramout and
Saba’a, constituting 11/43 (25.6 %), 8/43 (18.6 %), 4/43
(9.3 %), 3/43 (7 %) and 3/43 (7 %), respectively, as shown
in Table 4, Fig. 3. However, when calculating the percent-
age within individual entire residence, the highest propor-
tion of infection was found in the Saba’a representing
33.3 % followed by Al-Janad, Aden, Azaal, Tohama and
Hadhramout constituting 27, 24.4, 20, 16.7 and 10 %, in
this order, as indicated in Fig. 4.Table 2 Distribution of the cervical cancer cases by type of
cancer and HPV subtype
Cancer HPV31 HPV33 HPV35 HPV39 HPV45
+ve -ve +ve -ve +ve -ve +ve -ve +ve -ve
SCC 8 116 5 119 5 119 5 119 8 116
Ad 2 17 1 18 0 19 0 19 1 18
AdSC 1 2 1 2 2 1 0 3 1 2
Others 0 4 0 3 0 4 0 4 1 3
































Fig. 3 Description of the study population by HPV infection
and residence
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The mortality of cervical cancers is high in Yemen and
most cases are diagnosed late stage of the disease. In
fact, there is a complete paucity of data in this context
from Yemen; due to the absence of sufficient national
registries. Although, the prevalence of HPV is unknown
in Yemen, but data from the neighboring countries
showed increased burden. In present study, the relation-
ship between cervical cancer and the presence of the
high risk HPV (HR-HPV) subtypes HPV31, HPV33,
HPV35, HPV39, and HPV45 genome was tested. Data
on HPV type spreading is essential to assess the possible
impact of present and future HPV preventive strategies.
The prevalence and distribution of HPV genotypes dif-
fers significantly globally, and these variances might be
related to the complex geographical and biological inter-
action between different HPV types and host immuno-
genetic factors.
However, there is a lack of literature regarding the
burden of HPV in Yemen. To the best of our knowledge
there was only two study investigated the prevalence of
HPV in cervical cancer. The first one examined the pres-
ence of HPV16 and HPV18 in 84 cervical cancer tissue
samples that were previously categorized as harboring
HPV by immunohistochemistry using K1H8 (anti-HPV).
In the use of PCR testing for HPV subtypes 16 and 18;
62/84 (73.8 %) were identified positive for HPV subtype
16 and the remaining 22/84 (26.2 %) were negative.Table 3 Distribution of HPV subtypes by age
Age HPV31 HPV33 HPV35 HPV39 HPV45
+ve -ve +ve -ve +ve -ve +ve -ve +ve -ve
>35 0 31 3 28 1 3 2 29 2 29
36-45 6 54 2 57 1 0 60 4 56
46-55 4 61 2 70 2 59 2 70 2 70
56+ 1 36 0 37 3 69 1 36 3 34
Total 11 189 7 193 7 193 5 195 11 189Then again, on testing the specimens for HPV subtype
18; 23/84 (27.4 %) were found positive and the
remaining 61/84 (72.6 %) were revealed negative [19].
Another study from Yemen found that the prevalence of
HPV subtypes 52,56,58,59, and 66, among cases was 0.6,
0, 4, 3.3 and 0 % respectively [20].
Again the presence of the high risk HPV (HR-HPV)
subtypes HPV31, HPV33, HPV35, HPV39, and HPV45
was previously reported in a number of studies. Pro-
spective follow-up studies have proposed that persistent
HR-HPV infections play a crucial role in the progression
of CIN lesions and in the development of cervical can-
cer. The mean clearance time for the distinct HR-HPV
type was 16.5 months. HPV16 and HPV31 were the
most persistent infections (clearance times = 18.1 and
16.2 months, respectively), whereas HPV39 infections
cleared quickly. The mean copies per cell in HPV18/45,
HPV31, HPV33/52/58, and HPV39 infections were
higher in persisting HPV infections than in HPV infec-
tions that cleared, but the difference was not significant
[21]. In a study from Kuwait, investigated the distribu-
tion of HPV in 298 women with abnormal cervical cy-
tology, found that the prevalence of HPV33 was 9.9 %
[22], which was very high compared to our findings. Al-
though we found that the most prevalent HPV subtypesTable 4 Distribution of the HPV subtypes by residence
Region HPV31 HPV33 HPV35 HPV39 HPV45
+ve -ve +ve -ve +ve -ve +ve -ve +ve -ve
Azaal 2 36 1 39 2 38 1 39 4 36
Aden 3 42 0 45 2 44 2 43 4 41
Hadhramout 1 29 1 29 0 30 0 30 1 19
Al-janad 4 48 2 50 3 50 2 50 3 49
Tohama 1 24 3 21 0 24 0 24 0 24
Saba’a 1 8 1 8 1 8 0 9 0 9












Fig. 4 Description of the study population by HPV infection within
entire residence group
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the most prevalent HPV genotype, HPV31 followed by
HPV35 [23].
Regarding the relationship between age and HPV in-
fection in this study, it was observed that HPV31 and
HPV45 were relatively seen in younger ages compared
to HPV35 and HPV39; hence, HPV33 was more fre-
quent among elder women. However, the number of in-
fected women was so little to generate specific age range
for the studied women.
Moreover, there were considerable discrepancies re-
garding the distribution of the different HPV subtypes
among different regions. However, the explanations of
these findings require further onsite assessment of differ-
ent behavioral, social and other demographical measures.
A comprehensive screening for HPV subtypes linked to
Pap. Test may render more sufficient results for future
planning of potential vaccination program in Yemen.
However, the limitation of the present study include
its investigation included limited HPV subtypes.
In conclusion: HR-HPV31, HR-HPV33, HR-HPV35,
HR-HPV39, and HR-HPV45 are prevalent among Yem-
eni women with cervical cancer. Further, measures and
strategic plans are urgently required to reduce the bur-
den of cervical cancer in Yemen.Competing interests
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